Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?
REPLIPO
1 other identifier
observational
45
1 country
1
Brief Summary
To look for the replication of HHV6 by PCR in the skin, in these patients with haemopathies presenting an exanthema. This will make it possible to evaluate the prevalence of the positivity of this PCR in the skin. Then the investigator can investigate whether there is an association between the positivity of HHV6 PCR in the blood and / or skin and the viral etiology of the exanthema. If this association exists, it will make it possible to improve the diagnosis in the context of the exanthema and thus to improve the therapeutic management of these patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 13, 2016
CompletedFirst Submitted
Initial submission to the registry
March 31, 2017
CompletedFirst Posted
Study publicly available on registry
April 6, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 13, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 13, 2017
CompletedApril 6, 2017
March 1, 2017
6 months
March 31, 2017
March 31, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.
1 day
Interventions
To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
Eligibility Criteria
Any patient hospitalized in the Clinical Hematology and Cellular Therapy department of the CHU Amiens-Picardie between 01/01/2011 and 31/01/2016
You may qualify if:
- Supported for any type of hemopathy.
- Allograft, autografted or ungrafted haematopoietic stem cells
- Having presented an exanthema during hospitalization, for which a cutaneous biopsy had been performed
- Having had a blood test of the HHV6 virus by PCR at least within the previous 40 days or following the rash.
- Age greater than or equal to 18 years
- Patient informed of the protocol by post, not having refused within one month of sending the said courier.
You may not qualify if:
- Patient who refused the search.
- Patient whose HHV6 PCR in the blood was carried out at a distance of more than 40 days from the skin biopsy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU Amiens Picardie
Amiens, Picardie, 80054, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 31, 2017
First Posted
April 6, 2017
Study Start
December 13, 2016
Primary Completion
June 13, 2017
Study Completion
June 13, 2017
Last Updated
April 6, 2017
Record last verified: 2017-03